Therapeutic potential of BDNF and neurosteroids DHEA and DHEAS in an in vitro model of Parkinson’s disease
Parkinson's disease (PD) is progressive neurodegenerative disease characterized by the selective loss of dopaminergic neurons and accumulation of α-synuclein in the substantia nigra. Neurotoxins, such as rotenone and 6-hydroxidopamine are widely used to induce in vitro model of PD. These neurotoxins induce mitochondrial dysfunction and increase oxidative stress, leading to neuronal degeneration and cell death by apoptosis. Dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), along with brain-derived neurotrophic factor (BDNF) are involved in neuroprotection. Levels of both DHEA(S) and BDNF d